David G. McLeod - Concepedia

Author

David G. McLeod

Uniformed Services University of the Health Sciences ORCID

Also Known As

D G McLeod, DAVID G. MCLEOD, DAVID G. McLEOD, DAVID MCLEOD, DAVID McLEOD, DAvid G. McLeod, David G McLeod, David G Mcleod, David G. McLeod, David G. Mcleod

481

Publications

17.8K

Citations

H-Index

157

Concepts

All Affiliations

Uniformed Services University of the Health Sciences Walter Reed Army Institute of Research Walter Reed National Military Medical Center Armed Forces Institute of Pathology National Cancer Institute

About

David G. McLeod is an author at Uniformed Services University of the Health Sciences specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	86	5.6K
2	Health Sciences	8	8	848
3	Public Health	8	8	421
4	Engineering	2	2	57
5	Natural Sciences	2	2	41

David G. McLeod

192

Publications

16.5K

Citations

H-Index

Page 1

	Year	Citations
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma E. David Crawford, Mario A. Eisenberger, David G. McLeod, New England Journal of Medicine	1989	1.5K
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer Mario A. Eisenberger, Brent A. Blumenstein, E. David Crawford, New England Journal of Medicine	1998	867
Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men Ted O. Morgan, Steven J. Jacobsen, William F. McCarthy, New England Journal of Medicine	1996	421
Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy Christopher L. Amling, Robert H. Riffenburgh, Leon Sun, Journal of Clinical Oncology	2003	383
Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT–Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens Jun Miki, Bungo Furusato, Hongzhen Li, Cancer Research Stem Cell BiologyHigher Cd133 ExpressionHtert–immortalized Primary NonmalignantMedicinePathology	2007	364
NEOADJUVANT ANDROGEN ABLATION BEFORE RADICAL PROSTATECTOMY IN cT2bNxMo PROSTATE CANCER: 5-YEAR RESULTS Mark S. Soloway, KAPIL PAREEK, ROOHOLIAH SHARIFI, The Journal of Urology	2002	338
<i>PCGEM1</i>, a prostate-specific gene, is overexpressed in prostate cancer Vasantha Srikantan, Zhiqiang Zou, György Petrovics, Proceedings of the National Academy of Sciences	2000	337
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome György Petrovics, Aijun Liu, Syed Shaheduzzaman, Oncogene Systems BiologyGeneticsProstate Cancer TranscriptomeGene RegulationCancer Genomics	2005	337
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer Jennifer Cullen, Inger L. Rosner, Timothy C. Brand, European Urology	2014	311
Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer Mark S. Soloway, Roohollah Sharifi, Zev Wajsman, The Journal of Urology Surgical OncologyLaparoscopic Radical ProstatectomySurgeryUrogenital RadiologyOncology	1995	308

Page 1